Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.

MLA

Wretlind, Asger, et al. “Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.” Frontiers in Clinical Diabetes and Healthcare, vol. 3, Mar. 2022, p. 856485. EBSCOhost, https://doi.org/10.3389/fcdhc.2022.856485.

APA

Wretlind, A., Zobel, E. H., de Zawadzki, A., Ripa, R. S., Curovic, V. R., von Scholten, B. J., Mattila, I. M., Hansen, T. W., Kjær, A., Vestergaard, H., Rossing, P., & Legido-Quigley, C. (2022). Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Frontiers in Clinical Diabetes and Healthcare, 3, 856485. https://doi.org/10.3389/fcdhc.2022.856485

Chicago

Wretlind, Asger, Emilie Hein Zobel, Andressa de Zawadzki, Rasmus Sejersten Ripa, Viktor Rotbain Curovic, Bernt Johan von Scholten, Ismo Matias Mattila, et al. 2022. “Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.” Frontiers in Clinical Diabetes and Healthcare 3 (March): 856485. doi:10.3389/fcdhc.2022.856485.